These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 2139863

  • 1. Induction of pharmacological hypogonadotropism using gonadotropin-releasing hormone agonists in patients undergoing controlled ovarian stimulation.
    Lindner C, Braendle W, Lichtenberg V, Bettendorf G.
    Gynecol Obstet Invest; 1990; 29(2):132-9. PubMed ID: 2139863
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.
    Filicori M, Flamigni C, Cognigni G, Dellai P, Arnone R, Falbo A, Capelli M.
    J Clin Endocrinol Metab; 1993 Jul; 77(1):130-3. PubMed ID: 8325935
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
    Manna C, Rahman A, Sbracia M, Pappalardo S, Mohamed EI, Linder R, Nardo LG.
    Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
    [Abstract] [Full Text] [Related]

  • 9. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE, Macchi M, Montanini V, Mongioi A, Maugeri G, Vicari E, Coniglione F, Sipione C, D'Agata R.
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [Abstract] [Full Text] [Related]

  • 10. The effect of different LH-RH agonists on the levels of immunoreactive gonadotropins.
    Insler V, Lunenfeld E, Potashnik G, Levy J.
    Gynecol Endocrinol; 1988 Dec; 2(4):305-12. PubMed ID: 2976572
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A, Faure N.
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [Abstract] [Full Text] [Related]

  • 13. Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin.
    Broekmans FJ, Hompes PG, Lambalk CB, Schoute E, Broeders A, Schoemaker J.
    Hum Reprod; 1996 Jan; 11(1):55-60. PubMed ID: 8671156
    [Abstract] [Full Text] [Related]

  • 14. Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART.
    Sonntag B, Kiesel L, Nieschlag E, Behre HM.
    J Assist Reprod Genet; 2005 Aug; 22(7-8):277-83. PubMed ID: 16195824
    [Abstract] [Full Text] [Related]

  • 15. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 16. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism.
    Castelo-Branco C, Martínez de Osaba MJ, Martínez S, Fortuny A.
    Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772
    [Abstract] [Full Text] [Related]

  • 17. Treatment of hypogonadotropic hypogonadal male patients with the luteinizing hormone-relasing hormone (LH-RH) anolog D-Ser(TBU)6 EA10 LH-RH: transient disappearance of gonadotropin stimulation.
    Morel Y, Fournier M, Mazenod B, Tourniaire J, Mornex R.
    Fertil Steril; 1982 Jul; 38(1):85-91. PubMed ID: 6807722
    [Abstract] [Full Text] [Related]

  • 18. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot.
    Balasch J, Gómez F, Casamitjana R, Carmona F, Rivera F, Vanrell JA.
    Hum Reprod; 1992 Oct; 7(9):1230-4. PubMed ID: 1479003
    [Abstract] [Full Text] [Related]

  • 19. Reduction in pituitary desensitization and prolongation of gonadotropin release by estrogen during continuous administration of gonadotropin-releasing hormone in women: its antagonism by progesterone.
    Araki S, Chikazawa K, Motoyama M, Ijima K, Abe N, Tamada T.
    J Clin Endocrinol Metab; 1985 Mar; 60(3):590-8. PubMed ID: 3919050
    [Abstract] [Full Text] [Related]

  • 20. Pituitary responsiveness after administration of a GnRH agonist depot formulation: Decapeptyl CR.
    Broekmans FJ, Bernardus RE, Broeders A, Berkhout G, Schoemaker J.
    Clin Endocrinol (Oxf); 1993 Jun; 38(6):579-87. PubMed ID: 8334744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.